Needham keeps price targets on ACADIA and Recursion Pharmaceuticals
Needham kept its $35 price target on ACADIA Pharmaceuticals and $8 on Recursion Pharmaceuticals, Dow Jones Newswires reported.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Needham analysts kept their price target on ACADIA Pharmaceuticals shares at $35 and their target on Recursion Pharmaceuticals shares at $8. Dow Jones Newswires reported the move, citing ratings data from Benzinga.
Decisions like these do not change the analysts' view of the companies' business, but they confirm the previous valuation level for the stocks.
why it matters
For the market, a maintained price target usually matters little, because the analyst is not revising the valuation. Share price reactions tend to be muted unless the decision comes with a rating change or new revenue and earnings forecasts.
tags
instruments
sources
- ACADIA Pharmaceuticals Price Target Maintained With a $35.00/Share by Needham — Dow Jones Newswires, 19 October 2026 at 10:18 UTC
- Recursion Pharmaceuticals Price Target Maintained With a $8.00/Share by Needham — Dow Jones Newswires, 19 October 2026 at 10:44 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗